Cost per median overall survival month for abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Pilon, Dominic
Lefebvre, Patrick
Queener, Marykay
Ellis, Lorie
机构：
[1] Grp Anal Ltee, Montreal, PQ, Canada
[2] Janssen Sci Affairs LLC, Horsham, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e16080
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16080
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer
    Pilon, Dominic
    Queener, Marykay
    Lefebvre, Patrick
    Ellis, Lorie A.
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (08) : 777 - 784
  • [2] COST PER MEDIAN OVERALL SURVIVAL ASSOCIATED WITH ABIRATERONE ACETATE AND ENZALUTAMIDE FOR TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN COLOMBIA
    Aguirre, A.
    Guerrero, E.
    VALUE IN HEALTH, 2017, 20 (09) : A876 - A877
  • [3] Overall survival by race in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.
    McNamara, Megan Ann
    George, Daniel J.
    Ramaswamy, Krishnan
    Lechpammer, Stanislav
    Mardekian, Jack
    Schultz, Neil M.
    Wang, Li
    Baser, Onur
    Huang, Ahong
    Freedland, Stephen J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide
    Baciarello, Giulia
    Sternberg, Cora N.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 106 : 14 - 24
  • [5] Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer
    Zhang, Tian
    Zhu, Jason
    George, Daniel J.
    Armstrong, Andrew J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (04) : 473 - 485
  • [6] Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer
    La, Jennifer
    Wang, Lin
    Corrigan, June K.
    Lang, Deborah
    Lee, Michelle H.
    Do, Nhan V.
    Brophy, Mary T.
    Paller, Channing J.
    Fillmore, Nathanael R.
    JAMA NETWORK OPEN, 2024, 7 (08)
  • [7] Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients
    Efstathiou, Eleni
    Titus, Mark
    Wen, Sijin
    Troncoso, Patricia
    Hoang, Anh
    Corn, Paul
    Prokhorova, Ina
    Araujo, John
    Dmuchowski, Carl
    Melhem-Bertrandt, Amal
    Patil, Shiva
    Logothetis, Christopher J.
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (01): : 119 - 127
  • [8] Frailty and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Deol, Ekamjit Singh
    Luo, Suhong
    Sanfilippo, Kristen Marie
    Eisen, Seth A.
    Schoen, Martin W.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [9] Optimal sequencing of enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC)
    Maughan, Benjamin Louis
    Suzman, Daniel L.
    Nadal, Rosa Maria
    Bassi, Sunakshi
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [10] Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate
    Thomsen, Frederik Birkebaek
    Roder, Martin Andreas
    Rathenborg, Per
    Brasso, Klaus
    Borre, Michael
    Iversen, Peter
    SCANDINAVIAN JOURNAL OF UROLOGY, 2014, 48 (03) : 268 - 275
12345